Application of human Keratiocyte growth factor 1 in preparation of medicament for treating foot ulcers and leg ulcers of diabetes

A technology of keratinocytes and growth factors, used in the treatment of diabetic foot and leg ulcers, the application field of drugs, can solve problems such as stimulating the growth of epithelial cells

Inactive Publication Date: 2010-06-09
信立泰(苏州)药业有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It stimulates the growth of epithelial cells derived from various tissues, but has no direct effect on other cell types

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human Keratiocyte growth factor 1 in preparation of medicament for treating foot ulcers and leg ulcers of diabetes
  • Application of human Keratiocyte growth factor 1 in preparation of medicament for treating foot ulcers and leg ulcers of diabetes
  • Application of human Keratiocyte growth factor 1 in preparation of medicament for treating foot ulcers and leg ulcers of diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] The preparation of embodiment 1 freeze-dried preparation of the present invention

[0019] Active ingredient: Recombinant human keratinocyte growth factor 1 (you can buy palifermin or kepivance from Amgen, USA) or use conventional gene recombination technology to produce recombinant human keratinocyte growth factor 1, the method is as follows:

[0020] a. According to methods well known to those skilled in the field of biotechnology, artificially synthesize or use RT-PCR technology to clone the cDNA sequence of recombinant human keratinocyte growth factor 1 [fibroblast growth factor 7 (keratinocyte growth factor), Homo sapiens , Gene ID 2252], construct a recombinant plasmid, and transfect the engineered bacteria E.coli to express, obtain the genetically engineered bacteria expressing recombinant human keratinocyte growth factor 1, and carry out the expression of recombinant human keratinocyte growth factor 1 by fermenting and cultivating the genetically engineered bact...

Embodiment 2

[0024] The preparation of embodiment 2 spray formulations of the present invention

[0025] In order to facilitate transportation and storage, recombinant human keratinocyte growth factor 1 is prepared into a freeze-dried preparation, which can be prepared as a spray preparation according to the need: dissolve the freeze-dried preparation with physiological saline or a common medical solvent, and the concentration range of the active substance after dissolution is 50ng~100ug / ml, put it into a sprayer that meets the requirements, and then spray it.

Embodiment 3

[0026] The preparation of embodiment 3 gel formulations of the present invention

[0027] In order to facilitate transportation and storage, recombinant human keratinocyte growth factor 1 is prepared as a freeze-dried preparation, which can be prepared as a gel preparation according to the needs when used. The preparation method is as follows:

[0028] With the characteristics of polyoxyethylene-polyoxypropylene block copolymer (Pluronic) being liquid at low temperature and condensed into gel at body temperature, it is formulated as a gel companion of recombinant human keratinocyte growth factor 1 freeze-dried powder, which is compatible with recombinant human The keratinocyte growth factor 1 freeze-dried powder is stored together at low temperature (4-8°C). When used, dissolve the freeze-dried powder with a gel companion, suck it out and apply it to the affected area. The gel will be formed to cover the affected area under the action of body temperature, and the recombinant hu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses new purpose of a human Keratiocyte growth factor 1 applied to treatment of foot ulcers and leg ulcers of diabetes. In the invention, the biological activity of proliferation of epithelial cells is promoted by using the specificity of the human Keratiocyte growth factor 1 to repair the damage of the epithelial, and the structural restoration of the foot ulcers and leg ulcers of diabetes promoted to achieve the treatment of the foot ulcers and leg ulcers of diabetes.

Description

technical field [0001] The invention relates to a new application of human keratinocyte growth factor 1, in particular to the application in the preparation of medicines for treating diabetic foot and leg ulcers. Specifically, the human keratinocyte growth factor 1 is prepared into a preparation that can maintain biological activity and is suitable for external administration, and is used for treating diabetic foot and leg ulcers. Background technique [0002] Diabetic foot and leg ulcers are one of the most common complications of diabetes. The pathological basis is atherosclerosis of arteries and small arteries, leading to stenosis and blockage of blood vessels, resulting in ischemia and hypoxia of the tissues and organs dominated by them, resulting in gangrene or persistent ulcers. [0003] With the improvement of people's living standards and changes in lifestyle, the population is aging, and the incidence of diabetes is also on the rise, becoming the third largest chro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61P17/02A61P3/10A61L15/44
Inventor 赵斌彭红卫杨伟张宝华董佳里
Owner 信立泰(苏州)药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap